
|Articles|May 29, 2015
Dr Veena Shankaran Discusses Patient-Level Cancer Economics
Most of the research in cancer economics has been on total cost and cost effectiveness, which is why Veena Shankaran MD, MS, assistant professor in the division of medical oncology at the University of Washington, wanted to have a panel discussion on financial toxicity at the ISPOR 20th Annual Meeting.
Advertisement
Most of the research in cancer economics has been on total cost and cost effectiveness, which is why Veena Shankaran MD, MS, assistant professor in the division of medical oncology at the University of Washington, wanted to have a panel discussion on financial toxicity at the ISPOR 20th Annual Meeting.
The goal of the talk was to present strategies to measure financial burden and how to decrease the financial burden.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week
2
Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029
3
Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial
4
Impact of Automated Insulin Delivery on Type 2 Diabetes Measures
5




